Keywords
Diabetes Mellitus - Peripheral Nervous System Diseases - Confocal Microscopy
Palavras-chave
Diabetes Mellitus - Doenças do Sistema Nervoso Periférico - Microscopia Confocal
INTRODUCTION
Diabetic neuropathy (DN) is a very common, clinical condition worldwide, and it has
many different clinical forms, such as distal symmetric polyneuropathy (DSP), the
most frequent presentation and the main mechanism for the development of diabetic
foot.[1] It predominantly presents with positive, sensory (burning, tingling) and negative
symptoms (numbness, loss of sensation); however, it may develop asymptomatically.
It is usually associated with autonomic signs and symptoms and is rarely observed
with motor manifestations.[2] Approximately 20% of patients with DSP present neuropathic pain, which sometimes
becomes chronic and disabling.[3]
If the diagnosis is made early and correctly, it enables the proper treatment and
hinders the progression of the neuropathy, preventing serious complications.
Thus, obtaining the clinical history and performing a detailed neurological examination
are necessary to identify the signs of impaired nerve fibers.
Importantly, even in the absence of signs on the physical examination and the nerve
conduction study (NCS), small fiber neuropathy may still be present. Therefore, new
techniques have been developed to more accurately identify the early involvement of
these small-diameter myelinated (Aδ) and unmyelinated (C) fibers. Among these new
techniques, we highlight neurophysiologic, morphological, and autonomic testing methods
which, though currently recommended for the diagnosis of DSP, are not sensitive, such
as the NCS, and are invasive, like skin biopsy.
Recently, the sub-basal plexus of the human cornea, which is composed of small fibers,
was mapped through confocal microscopy, which enabled the characterization of its
pattern and the of distribution of nerve fibers in healthy subjects of both sexes
and different ages.[4]
In a series of 18 cases of diabetic patients compared with controls, the authors[5] demonstrated for the first time a significant reduction in the fiber density of
the sub-basal plexus by CCM, and highlighted that this examination may be used to
establish a morphological diagnosis, and it is rapid, noninvasive and reproducible
for the identification of DSP.
It is possible to estimate several aspects of the sub-basal plexus of the cornea,
such as the density of the fibers and nerve trunks, as well as their size, degree
of tortuosity and thickness, and, finally, the number of Langerhans cells per field.
These measurements are used in the qualitative and quantitative assessment of the
innervation of the cornea, enabling its comparison with various interest groups of
study.[6]
In the present study, we compared the morphological changes in the sub-basal corneal
epithelial plexus through in vivo CCM (IVCCM) in 35 diabetic patients with symptomatic
DSP to 55 control subjects in a Brazilian sample taken from a previous study.[7] In addition, we sought to determine a pattern of change regarding the stages of
severity of the DSP, comparing clinical, laboratory, and NCS variables.
METHODS
Patients
We selected 35 consecutive outpatient subjects with symptomatic DSP in neurology and
endocrinology and 55 healthy individuals in Hospital Universitário Antônio Pedro (HUAP)
from Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil, between November
2011 to March 2013. The present study was analyzed and approved by the HUAP Review
Board on June 17, 2011 (CAAE: 0144.0.258.000–11). The patients were informed about
all the research steps, and they read and signed two copies of the consent form before
their inclusion in the study.
Study design
Subjects who met the inclusion criteria for the group of diabetic patients underwent
clinical, laboratory, and neurophysiologic studies, as well as the performance of
CCM. The 55 control subjects were submitted to a clinical assessment, and those who
did not present relevant changes in the neurological examination underwent the CCM.
The study included patients between 21 and 70 years of age. Patients in the diabetic
group had to fulfill the current criteria of the American Diabetes Academy for the
diagnosis of type-2 diabetes mellitus, present neuropathic symptoms such as paresthesia,
pain, or imbalance, and have a Neuropathy Disability Score (NDS) > 3 for the establishment
of the clinical diagnosis of DSP. We excluded patients with a history of trauma or
corneal diseases, previous eye surgeries, those who had used contact lenses less than
24 hours before the CCM, those who had a history of conditions that could compromise
the cornea and/or peripheral nerve, patients who, for fewer than 6 months, had used
drugs that are potentially toxic to the nerves and/or cornea, and/or had cognitive
and/or sensory deficits that impair the scores on the scales or the exam.
The clinical evaluation was based on data from the history, the physical and neurological
examinations, and specific scales for neuropathy, neuropathic pain, and disability.
The NCS was performed using an electromyograph (Nihon Kohden Corp., Shinjuku, Tokyo,
Japan).
We applied the NDS to assess the severity of the neuropathy,[8] the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)[9] to evaluate the neuropathic pain, and the modified Rankin scale for disability,[10] all validated for the Portuguese language.
We used the Heidelberg Retina Tomograph III Rostock Corneal Module (HRT3 RCM, Heidelberg
Engineering GmbH, Heidelberg, Germany) confocal microscope to capture images of the
sub-basal corneal epithelial plexus. These tests were performed by an ophthalmologist
who was an expert in the field.
The patients' corneas were anesthetized using a drop of benoxinate hydrochloride at
0.4% and lubricated each eye with carbomer 0.2% eye gel, as well as the surface of
the TOMOCAP (Heidelberg Engineering GmbH). Soon after, the patient was positioned
comfortably and appropriately for the beginning of the study ([Figure 1]).
Figure 1 The HRT3 RCM confocal microscope.
Images from the five layers of the corneas were obtained. After identification of
the epithelium, the objective lenses were positioned at 0 mm in depth, always exploring
a fixed field of 0.16 mm2. From this point, the lenses were deepened to the subepithelial layer, where multiple
images of the sub-basal plexus were obtained. The distance between each image was
of ∼ 1 µm.[11]
The five best photos of the sub-basal plexus of the cornea of each eye were selected.
The images of individuals from both groups were subjected to a blinding process. Each
image was analyzed manually and separately by three observers for the following previously-established
parameters: the number of fibers and of the Langerhans cells per field, the degree
of tortuosity, and the thickness of the fibers.
The degrees of tortuosity established were: 1 for linear and parallel fibers; 2 for
tortuous and non-parallel fibers, but in the same direction; and 3 for tortuous fibers
not in the same direction. The degrees of thickness were classified as: 1 for thick
fibers; 2 for fibers of medium thickness; and 3 for thin fibers.
Statistical analysis
Comparison of the findings of the CCM in both groups
The results of the CCM in the diabetic and control patients were compared by means
and proportion tests. The Kolmogorov-Smirnov and the Shapiro tests were used to verify
the normality of the continuous or discrete variables, and the mean differences were
evaluated through the t-test or Mann-Whitney U test.
The percentage differences noted regarding the qualitative variables were evaluated
using the Chi-squared statistic.
All statistical analyses were performed using the Statistical Package for Social Sciences
(SPSS for Windows, SPSS Inc., Chicago, IL, US) software, version 16.0.
RESULTS
Description of the study population
We evaluated 90 individuals, 35 diabetic patients with symptomatic DSP (39%) and 55
control subjects (61%). The differences between the control and diabetic groups were
observed in the following variables, respectively: age (44.9 ± 13.24 years versus
57.02 ± 10.4 years; p < 0.001); fiber density (29.7 ± 10.2 versus 16.6 ± 10.2; p < 0.001); mean number of fibers (4.76 ± 1.30 versus 3.14 ± 1.63; p < 0.001); mean number of Langerhans cells (4.64 ± 8.05 versus 7.49 ± 10.3; p = 0.035); tortuosity (p < 0.05); and thickness (Chi-squared p < 0.05) ([Table 1]).
Table 1
Demographic features, CCM and NCS results, laboratory and clinical findings
|
Variables
|
Diabetics (n = 35)
|
Controls (n = 55)
|
p-value
|
|
Male sex (%)
|
25.7%
|
45.5%
|
|
|
Age (mean ± SD)
|
57.2 ± 10.4
|
44.9 ± 13.24
|
< 0.0011
|
|
Number of fibers (mean ± SD)
|
3.14 ± 1.63
|
4.76 ± 1.30
|
< 0.0012
|
|
Fiber density (mean ± SD)
|
16.6 ± 10.2
|
29.7 ± 10.2
|
< 0.0012
|
|
Number of Langerhans cells (mean ± SD)
|
7.49 ± 10.3
|
4.64 ± 8.05
|
0.0351
|
|
Tortuosity (%)
|
Normal
|
−
|
3.6%
|
< 0.05
|
|
Paralell
|
5.7%
|
45.5%
|
|
Non-parallel
|
82.9%
|
45.5%
|
|
Not in the same direction
|
11.4%
|
5.5%
|
|
Thickness (%)
|
Normal
|
−
|
3.6%
|
< 0.05
|
|
Thin
|
74.3%
|
29.1%
|
|
Medium
|
25.7%
|
63.3%
|
|
Large
|
−
|
3.6%
|
|
Time since the onset of diabetes (mean ± SD)
|
9.89 ± 6.87
|
−
|
−
|
|
Time since the onset of symptoms (mean ± SD)
|
3.49 ± 2.56
|
−
|
−
|
|
Metabolic syndrome (yes: %)
|
65.7%
|
−
|
−
|
|
Diabetic foot (yes: %)
|
14.3%
|
−
|
−
|
|
Macrovascular complication (yes: %)
|
25.7%
|
−
|
−
|
|
Microvascular complication (yes: %)
|
57.1%
|
−
|
−
|
|
Retinopathy (yes: %)
|
45.7%
|
−
|
−
|
|
Nephropathy (yes: %)
|
37.1%
|
−
|
−
|
|
Pain (yes: %)
|
37.1%
|
−
|
−
|
|
Treatment: insulinotherapy (%)
|
48.6%
|
−
|
−
|
|
Glycated hemoglobin (%)
|
7.54 ± 2.14
|
|
|
|
Hypertension (yes: %)
|
85.7%
|
−
|
−
|
|
Dyslipidemia (yes: %)
|
45.7%
|
−
|
−
|
|
BMI Kg/m2(mean ± SD)
|
29.1 ± 5.49
|
−
|
−
|
|
Mild or moderate disability (%)
|
34.3%
|
−
|
−
|
|
Neuropathy Disability Score
|
Mild
|
31.4%
|
−
|
−
|
|
Moderate
|
31.4%
|
−
|
−
|
|
Severe
|
37.1%
|
−
|
−
|
Abbreviations: BMI, Body Mass Index; CCM, corneal confocal microscopy; NCS, nerve
conduction study; SD, standard deviation.
In the diabetic group, 31.4% of the patients had mild DSP (NDS: 3 to 5), 31.4% had
moderate (NDS: 6 to 8), and 37.1% had severe DSP (NDS: 9 to 10) ([Table 1]).
Comparison of the CCM findings between the groups
For the mean number of fibers and density, we found a statistically significant difference
between the control and diabetic groups (p < 0.001). A statistically significant difference was also noted when the means of
the Langerhans cells (p = 0.035) were compared. The equality of the variances was tested for several fibers
with the Levene test (p = 0.367) ([Table 2], [Figure 2]).
Figure 2 Comparison of the findings of IVCCM between the diabetic and control study groups.
Table 2
Summary and dispersion measurements of CCM variables according to study groups for
the entire population
|
|
N
|
Mean
|
SD
|
95%CI
|
Min.
|
Max.
|
|
Number of fibers
|
Healthy controls
|
55
|
4.76*
|
1.305
|
4.41
|
5.12
|
2
|
7
|
|
Diabetics
|
35
|
3.14*
|
1.630
|
2.58
|
3.70
|
0
|
7
|
|
Total
|
90
|
4.13
|
1.637
|
3.79
|
4.48
|
0
|
7
|
|
Density
|
Healthy controls
|
55
|
29.7*
|
10.201
|
27.56
|
31.97
|
12.50
|
43.75
|
|
Diabetics
|
35
|
16.6*
|
10.184
|
16.14
|
23.14
|
0.00
|
43.75
|
|
Total
|
90
|
25.83
|
10.229
|
23.69
|
27.97
|
0.00
|
43.75
|
|
Langerhans cells
|
Healthy controls
|
55
|
4.64*
|
8.054
|
2.46
|
6.81
|
0
|
45
|
|
Diabetics
|
35
|
7.49*
|
10.305
|
3.95
|
11.03
|
0
|
44
|
|
Total
|
90
|
5.74
|
9.049
|
3.85
|
7.64
|
0
|
45
|
Abbreviations: 95%CI, 95% confidence interval; CCM, corneal confocal microscopy; Max.,
maximum; Min., minimum; SD, standard deviation.
Note: *Differences in means with p < 0.05.
The variables were reclassified in tortuosity (fibers with no tortuosity or tortuousness)
and thickness (absent or thin fibers, medium or large fibers). We observed statistically
significant differences in the percentage categories of tortuosity and the thickness
between the groups (Chi-squared p < 0.001) ([Table 1]).
Pattern of the morphological changes
The pattern of the morphological changes was determined in three stages by comparing
the clinical, laboratory, and NCS findings of the CCM. The following variables were
statistically different from the mean in the categories of mild and moderate neuropathy
/ severe: the duration of the diabetes and the SNAP of the sural nerve (p <0.05). The mean differences in symptom duration, glycated hemoglobin (HbA1C), CV,
and compound muscle action potential (CMAP) of the fibular nerve were observed between
mild and severe neuropathy ([Table 3], [Figure 3]).
Table 3 Demographic, clinical, laboratory, CCM, and NCS variables according to severity
stages
|
Neuropathy
|
|
Mild (n = 11)
|
Moderate (n = 11)
|
Severe (n = 13)
|
|
Age (years)[1]
|
54.3 ± 13.6
|
60.7 ± 7.97
|
53.3 ± 15.0
|
|
BMI[2] (Kg/m[2])
|
30.4 ± 5.9
|
29.2 ± 5.28
|
28 ± 2.0
|
|
Time since the onset of diabetes (years)[1]
|
4.18 ± 4.2*§
|
11.7 ± 5.7*§
|
17.3 ± 7.1*§
|
|
Time since the onset of symptoms (years)[1]
|
1.91 ± 14.5**§
|
3.30 ± 2.9
|
6.67 ± 2.9**§
|
|
HbA1C[1] (%)
|
6.27 ± 1.35
|
7.40 ± 1.57
|
7.0 ± 1.0
|
|
CCM
|
Numberoffibers[2]
|
3.82 ± 1.6
|
3.20 ± 1.8
|
3.00 ± 2.0
|
|
Langerhanscells[1]
|
7.0 ± 9.8
|
10.0 ± 14.1
|
2.33 ± 4.0
|
|
Density[2]
|
23.8 ± 10.0
|
20 ± 11.3
|
18.75 ± 12.5
|
|
NCS
|
Sural amplitude uV(d[1]/e[2])
|
11.3 ± 4.1*§/11.64 ± 3.2[§]
|
4.0 ± 1.3*§/6.5 ± 4.7[§]
|
3.0 ± 1.7*§/4.0 ± 3.6[§]
|
|
Fibular conductionvelocity in m/s(d[2]/e[2])
|
47.1 ± 4.1[§]/46.3 ± 3.1[§]
|
43.9 ± 4.5[§]/44.2 ± 4.8[§]
|
41.3 ± 4.9[§]/41.6 ± 3.5[§]
|
|
Fibular CMAP mV(d[2]/e[1])
|
4.45 ± 1.7/4.5 ± 2.0**§
|
4.7 ± 1.89/4.1 ± 1.4**§
|
5.0 ± 1.7/3.6 ± 0.6**§
|
Abbreviations: BMI, Body Mass Index; CCM, corneal confocal microscopy; CMAP; d; e;
HbA1C, glycated hemoglobin; mV; NCS, nerve conduction study; uV.
Notes:
1 One-way anaçysis of variance (Tukey).
2 Kruskal-Wallis test.
* Difference between mild and moderate/severe.
** Difference between mild and severe.
§
p < 0.05.
Figure 3 Comparison of the morphological changes in three stages of severity by clinical,
laboratory, and NCS variables and the findings of IVCCM.
Regarding the NCS, we observed statistically significant differences regarding the
mean SNAP of the sural nerve and the three stages of severity. In the conduction velocity
of the fibular nerve, differences in the means were noted between patients with mild
and severe conditions (p < 0.05). And, in relation to the fibular CMAP, these differences were significant
between patients with mild and severe neuropathy ([Table 3]).
In the subgroup of the diabetic patients with mild neuropathy, or small-fiber neuropathy,
∼ 90% were female, aged between 27 and 70 years, ∼ 80% had had the diagnosis of DM
and the symptoms for fewer than 5 years, and all were using oral hypoglycemic agents,
without need for insulin therapy. The mean body mass index (BMI) was of 30.4 kg/m2, 36% reported pain as a symptom, and 100% had an NCS within the normal range. Of
these, 27% had other microvascular complications and a mean of HbA1c of 6.2%. The
mean number of fibers was 3.8 ± 1.6, and the mean density was of 23.8 ± 10. As for
the Langerhans cells, the mean number was 7 ± 9.8. About 90% had no parallel fibers,
and 64% had thin fibers ([Table 3]).
In the subgroup of patients with moderate neuropathy, 100% were female, aged between
49 and 69 years, with a diabetes duration of 7 to 20 years, a mean BMI of 29.2 kg/m2, and 54% had pain. Furthermore, 64% were dependent on insulin therapy, 90% had pure
sensory neuropathy on the NCS, 45% exhibited at least 1 microvascular complication,
and their mean HbA1C was of 7.4%. About 30% had a mild disability. The mean number
of fibers was 3.2 ± 1.8, and the mean density was of 20 ± 11.3. The Langerhans cells
had a mean number of 10.0 ± 14.1. About 90% had no parallel fibers, and 85% had thin
fibers ([Table 3]).
Among the patients with severe neuropathy, 61% were male, aged between 40 and 70 years.
The time since their diagnosis of diabetes ranged from 24 to 30 years, their mean
BMI was of 28 kg/m2, and 23% had neuropathic pain. Approximately 80% were using insulin, 38% had diabetic
foot complications, and 100% experienced sensorimotor DSP according to the NCS. The
mean HbA1c was of 7.0%. About 90% had other microvascular complications and 61.5%
were classified as having mild or moderate degrees of disability. Regarding the CCM,
the mean number of fibers was 3.0 ± 2.0, with a mean density of 18.75 ± 12.5. The
mean number for the Langerhans cells was 2.3 ± 4.0. None these patients had parallel
fibers and 85% had thin fibers ([Table 3]).
Positive relationships were found between the duration of the diabetes and: the diabetes
symptoms (r = 0.791; p < 0.01), the NDS (r = 0.580; p < 0.01), the duration of the symptoms (r = 0.487; p < 0.01), and the NDS (r = 0.531; p < 0.01) ([Table 4]).
Table 4
Pearson and Spearman correlation regarding the clinical variables, laboratory tests,
CCM, and NCS
|
|
Clinical and laboratory
|
CCM
|
NCS
|
|
|
Age
|
TD
|
TS
|
BMI
|
HbA1C
|
NDS
|
Dens
|
LC
|
ARS
|
ALS
|
CVRF
|
CVLF
|
RFA
|
LFA
|
|
Clínical and laboratory
|
Age[2]
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TD[2]
|
0.162
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TS[2]
|
0.101
|
0.791[**]
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
BMI[2]
|
-0.158
|
-0.340[*]
|
-0.075
|
1
|
|
|
|
|
|
|
|
|
|
|
|
HbA1C[2]
|
-0.206
|
0.325
|
0.167
|
-0.220
|
1
|
|
|
|
|
|
|
|
|
|
|
NDS[2]
|
0.011
|
0.580[**]
|
0.487[**]
|
-0.113
|
0.537[**]
|
1
|
|
|
|
|
|
|
|
|
|
CCM
|
Dens[1]
|
-0.432[**]
|
-0.085
|
0.043
|
0.047
|
-0.174
|
-0.405[*]
|
1
|
|
|
|
|
|
|
|
|
LC[2]
|
0.315
|
0.042
|
-0.033
|
0.183
|
0.017
|
-0.038
|
-.318
|
1
|
|
|
|
|
|
|
|
NCS
|
ARS[2]
|
-0.303
|
-0.677[**]
|
-0.437[*]
|
0.023
|
-0.316
|
-0.863[**]
|
.200
|
-.086
|
1
|
|
|
|
|
|
|
ALS[1]
|
-0.293
|
-0.538[**]
|
-0.247
|
0.173
|
-0.145
|
-0.581[**]
|
.074
|
.084
|
.567[**]
|
1
|
|
|
|
|
|
CVRF[1]
|
-0.305
|
-0.437[*]
|
-0.261
|
0.057
|
-0.278
|
-0.637[**]
|
0.386[*]
|
0.139
|
0.584[**]
|
0.485[*]
|
1
|
|
|
|
|
CVLF[1]
|
-0.366[*]
|
-0.260
|
-0.262
|
-0.137
|
-0.309
|
-0.632[**]
|
0.446[*]
|
-0.153
|
0.556[**]
|
0.424[*]
|
0.860[**]
|
1
|
|
|
|
RFA[1]
|
-0.173
|
-0.172
|
-0.010
|
0.156
|
-0.224
|
-0.274
|
0.304
|
0.149
|
0.066
|
-0.047
|
0.499[**]
|
0.364[*]
|
1
|
|
|
LFA[2]
|
0.031
|
-0.165
|
-0.201
|
0.192
|
-0.623[**]
|
-0.405[*]
|
0.185
|
-0.063
|
0.199
|
-0.162
|
0.406[*]
|
0.349
|
0.362[*]
|
1
|
Abbreviations: ALS, amplitude of the left sural nerve; ARS, amplitude of the right
sural nerve; BMI, Body Mass Index; CCM, corneal confocal microscopy; CVLF, conduction
velocity of the left fibular nerve; CVRF, conduction velocity of the right fibular
nerve; Dens, density; HbA1C, glycated hemoglobin; LC, Langerhans cells; LFA, left
fibular amplitude; NCS, nerve conduction study; NDS, Neuropathy Disability Score;
RFA, right fibular amplitude; TD, time since the onset of diabetes; TS, time since
the onset of symptoms.
Notes:
1 Pearson correlation.
2 Spearman correlation.
*
p < 0.05.
**
p <0.01.
Regarding the results of the NCS, negative correlations were observed: inversely proportional
relationships between the NDS and the SNAP of the sural nerve (r = -0.863 and r = -0.581
respectively; p < 0.01), the NDS and the fibular nerve CV (r = -0.637 and r = -0.632 respectively;
p < 0.01), and the NDS and the CMAP of the fibular nerve (r = -0.405; p < 0.05).
Considering the results of the CCM, inverse relationships were found between the fiber
density and age (r = - 0.432; p < 0.01) and the fiber density and the NDS (r = -0.405; p < 0.05). Another highlight is a positive relationship between the CV of the fibular
nerve and the fiber density (r = 0.386 and r = 0.446 respectively; p < 0.05) ([Table 4]).
DISCUSSION
The involvement of the cornea in diabetic patients has been reported over the years
by several authors.[12] The advent of CCM enabled the direct visualization, in the layers of the cornea,
of the nerve fibers and the impairment in patients with DN.[5]
Considering the techniques available for the diagnosis of DSP, this method has attracted
great interest from the scientific community because it is fast and non-invasive.
Since then, several studies have been conducted to evaluate the best technique, the
best parameters, and, primarily, a standardization of the method. To this end, some
researchers[13] have endeavored to characterize the distribution of the sub-basal plexus of the
cornea in healthy individuals, their morphology, and differences between genders and
age groups.
We found statistically significant differences (p < 0.05) in all the CCM variables studied. In the diabetic group, there was a considerable
reduction in the number of fibers, fiber density, as well as increased number of Langerhans
cells. In addition, a higher tortuosity index and a lower degree of thickness were
observed when compared with controls. This same pattern of changes is mentioned in
studies performed with the same purposes as the present one.[5]
[6]
[11]
[14]
[15]
[16]
[17]
[18]
[19]
These data are similar to those of several studies[20] conducted to identify the clinical variables as risk factors for the development
and progression of DSP.
We found a positive relationship between the CCM parameters and the modified Rankin
Scale, which demonstrates the correlation between the progression of the DSP and disability.
Corroborating this finding was the worsening of functionality to evaluate the quality
of life and depression, according to the severity of DSP in diabetics previously highlighted.[8]
The results of the NCS, represented by the SNAP of the sural nerve, CV, and CMAP of
the fibular nerve, corresponded to the findings already widely demonstrated[21]
[22]
[23]
[24] in the progression of diabetic DSP. There was an inverse relationship between these
parameters and the NDS, the values of HbA1c, and the duration of diabetes and symptoms.[21]
[22]
[23]
[24]
Regarding the CCM parameters, inverse relationships between age and fiber density,
and fiber density and the NDS were observed ([Figure 4]). Moreover, a positive correlation was found between the CV of the fibular nerve
and fiber density.
Figure 4 (A) Example of thick (thickness: 3), linear, and parallel (tortuosity: 1) fibers, with
7 fibers and 1 Langerhans cell. (B) Example of medium fibers (thickness: 2), somewhat tortuous and not parallel, but
in the same direction (tortuosity: 2), and with 5 fibers and 1 Langerhans cell. (C) Example of thin fibers (thickness: 1), very tortuous and without direction (tortuosity:
3), with 2 fibers and 14 Langerhans cells. (D) Example of absence of fibers and 9 Langerhans cells. Images extracted from the database
of the present study.
There is no consensus in the literature about the effect of aging on the density of
the fibers of the sub-basal corneal epithelial plexus.[25] However, a study[26] showed a yearly linear decrease of 0.9% in fiber density, corroborating the results
of the present study.
There seems to be a proportional reduction in the density of the fibers of the sub-basal
plexus of the cornea along the natural history of diabetic DSP. Furthermore, it is
believed that the fibers become thinner due to the process of axonal degeneration
in the course of the disease. The increased tortuosity index and the decrease in thickness
were attributed to axonal degeneration and regeneration in DSP, as in the pattern
of the histopathologic findings in the peripheral nerve (sprouting), suggesting a
chronic, axonal damage.[27]
A significant increase in the number of Langerhans cells was found in the diabetic
group compared with the controls, with greater distribution among patients with mild
and moderate forms of DSP, corroborating a previous study,[11] which may indicate the contribution of the immune mechanism in the pathogenesis
and a perpetuation of the axonal impairment.
In the literature, few papers have been published demonstrating the efficacy of CCM
in identifying the regeneration of nerve fibers in the sub-basal plexus of the cornea
after pancreas transplantation in patients with type-1 diabetes mellitus and after
improvement of the risk factors for DSP in patients with type-2 diabetes mellitus,
whereas functional methods of assessing the peripheral nerve, such as NCS and the
Quantitative Sensory Test (QST), were not able to detect such improvement.[28]
Several comparisons with other diagnostic methods, such as NCS, skin biopsy, and the
QST, have shown that CCM had greater sensitivity and specificity in identifying diabetic
DSP in the early stage, when there is only the involvement of small fibers. Moreover,
it is rapid, noninvasive, reproducible, and enables multiple assessments throughout
the evolution of the patient. The reduced fiber density in the epithelial sub-basal
corneal plexus has a strong correlation with the degree of involvement of the peripheral
nerve, which shows this method as a possible diagnosis for testing in the evolution
of the severity of the neuropathy. These features make this method very promising
for use not only in the clinical practice, but also in longitudinal studies and clinical
trials, to evaluate the therapeutic efficacy of certain drugs in diabetic DSP.[6]
An increasing number of articles on the use of IVCM to quantify diabetic neuropathy
has demonstrated a reduction in corneal sub-basal nerve fiber density and an increase
in nerve fiber tortuosity in diabetes, correlated with the stage or severity of the
peripheral neuropathy.[29]
In summary, to date, several groups[25] have employed CCM of the corneal sub basal nerves in diabetic subjects to identify
patients with minimal neuropathy, quantify the severity of the neuropathy, and follow
the progression or assess the therapeutic response in DN. In vivo CCM has shown moderate-to-high
specificity in the diagnosis of DN[16] and the usefulness of the corneal nerves as DN biomarkers.[12]
[16]
[19]
In conclusion, CCM is a fast, non-invasive method, with good reproducibility, which
contributes to the identification of changes in corneal innervation in patients with
diabetic DSP. In addition, the reduction in fiber density of the epithelial sub-basal
plexus of the cornea has a high correlation with the degree of involvement of the
peripheral nerve, that is, the severity of the neuropathy, standing out as a possible
diagnostic and evolutionary test of the disease. These characteristics of the method
favor its applicability both in the clinical practice and in longitudinal studies,
such as clinical trials.
The method's limitations include the high cost of the device, the need for a qualified
professional, and the fact that there are still few studies on standardization.
Future research with larger samples is necessary to standardize and consolidate the
method as a diagnostic test for diabetic DSP and also for other small-fiber neuropathies.
